Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Masataka Amisaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4153-4036; OpenAlex author ID A5076427318. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 11

  1. Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer. Co-author DOI 10.1093/jjco/hyag044↗
  2. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08426-5↗
  3. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  4. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  5. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Co-author DOI 10.1038/s41586-022-04735-9↗
  6. Reprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion. Co-author DOI 10.1158/2159-8290.cd-21-1690↗
  7. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2019.03.010↗
  8. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13260↗
  9. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Can… Co-author DOI 10.21873/anticanres.12883↗
  10. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00595-016-1308-6↗
  11. Nicotine enhances the malignant potential of human pancreatic cancer cells via activation of atypical protein kinase C. Co-author DOI 10.1016/j.bbagen.2016.07.008↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vinod P. Balachandran · 4 shared papers, 2022–2025 · strength 0.54
  2. Benjamin D. Greenbaum · 3 shared papers, 2022–2025 · strength 0.42
  3. Taha Merghoub Merghoub · 3 shared papers, 2022–2025 · strength 0.42
  4. Zachary M. Sethna · 3 shared papers, 2022–2025 · strength 0.42
  5. Luis Alfonso Rojas · 3 shared papers, 2022–2025 · strength 0.42
  6. Kevin C. Soares · 3 shared papers, 2022–2025 · strength 0.42
  7. Teruhisa Sakamoto · 5 shared papers, 2016–2019 · strength 0.39
  8. Akihiro Ohmoto · 2 shared papers, 2025 · strength 0.32
  9. Yoshiyuki Fujiwara · 3 shared papers, 2018–2019 · strength 0.29
  10. Taro Shibuki · 1 shared paper, 2026 · strength 0.28
  11. Tomoyuki Satake · 1 shared paper, 2026 · strength 0.28
  12. Shuichi Mitsunaga · 1 shared paper, 2026 · strength 0.28
  13. Mitsuhito Sasaki · 1 shared paper, 2026 · strength 0.28
  14. Masafumi Ikeda · 1 shared paper, 2026 · strength 0.28
  15. Hiroshi Imaoka · 1 shared paper, 2026 · strength 0.28
  16. Tomonao Taira · 1 shared paper, 2026 · strength 0.28
  17. Kanae Inoue · 1 shared paper, 2026 · strength 0.28
  18. Jedd D. Wolchok · 2 shared papers, 2022–2025 · strength 0.25
  19. Ei Uchinaka · 2 shared papers, 2018–2019 · strength 0.17
  20. Masaki Morimoto · 2 shared papers, 2018–2019 · strength 0.17
  21. Olca Baştürk · 1 shared paper, 2025 · strength 0.15
  22. Ryan Sugarman · 1 shared paper, 2025 · strength 0.15
  23. Anna M. Varghese · 1 shared paper, 2025 · strength 0.15
  24. Özlem Türeci · 1 shared paper, 2025 · strength 0.15
  25. T. Peter Kingham · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.